Belite Bio To Participate In Four Upcoming Investor Conferences
- Wells Fargo 21st Annual Healthcare Conference (Boston, MA)
- September 8, 2026, at 8:45 am ET, fireside chat
- September 11, 2026, at 10:55 am ET, fireside chat
- September 14, 2026, at 7:45 am ET, fireside chat
- September 15, 2026, at 9:00 am ET, fireside chat
Webcast Link Instructions
Webcasts of the presentations can be accessed under“Events” in the investor relations section of the Belite Bio website at: . The replays will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio's lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at .
Media and Investor Relations Contacts:
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment